ORBIMED ADVISORS LLC purchased $15.0M of QTTB (indirect holdings)

ORBIMED ADVISORS LLC purchased 1,875,000 indirectly-held shares of Q32 Bio Inc. (QTTB) at $8.00 ($15.00M total) across 2 trades on 2026-05-28. Filed jointly with OrbiMed Capital GP VII LLC (Director) and OrbiMed Genesis GP LLC (Director).

Original reporting
SEC EDGAR · ORBIMED ADVISORS LLC, OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC
Published Jun 2, 2026, 1:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QTTB
Bullish
high confidence
Mentioned
$QTTB
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QTTBBullishMed
01

Why it matters

The sizable buy may be interpreted as a vote of confidence, potentially supporting the stock price in the short term.

02

Market read

First‑report insider purchase provides fresh material for traders evaluating Q32 Bio.

03

What to watch

Potential upcoming clinical data releases or financing needs not disclosed.

Relevance 8/10Novelty 7/10Timing: filing day today

Background

Form 4 filing from SEC reveals an insider purchase by OrbiMed Advisors, a director and 10% owner of Q32 Bio.

Company-level read

Ticker impact

$QTTBBullishHigh confidence
Context

OrbiMed Advisors bought 1,875,000 shares of Q32 Bio at $8 each, a $15 M open‑market purchase disclosed on Form 4.

Expected impact

potential upward pressure as the market prices in insider confidence

Evidence & confidence

The $15 M stake by a director and 10% owner is a material insider buy, likely viewed as a bullish signal.

Market effects

Biotech sector may see modest uplift as insider buying signals pipeline confidence.

U.S. biotech investors could react positively, limited broader market effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

The purchase could be a defensive move to maintain control rather than a growth bet.

Key entities

  • Q32 Bio Inc.

    Biotech firm developing therapies, ticker QTTB.

  • OrbiMed Advisors LLC

    Director and 10% owner of Q32 Bio.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QTTBMedAI 8/10

Q32 Bio Reports Q3 Results; Advances Bempikibart Toward Phase 3 In Alopecia Areata

Q32 Bio (QTTB) reported Q3 2026 results, with R&D expenses rising to $5.1M and net loss increasing to $8.9M. The company presented Phase 2a trial data for bempikibart, showing a 35.3% mean reduction in SALT scores for alopecia areata patients. Q32 Bio plans to initiate a Phase 3 trial in early 2027 and has $289.6M in cash reserves. The stock is currently trading at $8.81, up 0.57%.

$QTTBLow

Q32 Bio 3Q 2026: Net loss $8.9M, EPS $(0.26) — 10-Q Summary

Q32 Bio reported a Q3 2026 net loss of $8.9M, up 20.7% YoY, with EPS loss narrowing to $0.26. The company's bempikibart study showed improved SALT scores and no serious adverse events. Q32 plans regulatory discussions in Q4 2026 and aims to advance bempikibart in early 2027. Akebia will develop ADX-097 after the asset sale.

$QTTBMedAI 8/10

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio reported Q3 2026 results, highlighting positive SIGNAL-AA clinical trial data for bempikibart, a treatment for alopecia areata. The company presented 36-week results and 16-week off-drug findings at EADV Congress, showing durable responses. Q32 Bio plans to initiate a registration-directed program in 1H 2027 and has $289.6M in cash. The company also strengthened its leadership team and expects Phase 3 topline results from the planned program.